Cargando…
Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters
BACKGROUND: Hand-foot syndrome (HFS) is a side effect of skin related to pegylated liposomal doxorubicin (PLD) application. Moderate to severe hand-foot syndrome (MSHFS) might have a serious impact on patients’ quality of life and treatment. However, information on risk factors for the development o...
Autores principales: | Liang, Guohua, Ma, Wenjie, Zhao, Yanfang, Liu, Eryu, Shan, Xiaoyu, Ma, Weiwei, Tang, Dabei, Li, Liru, Niu, Xingjian, Zhao, Wenhui, Zhang, Qingyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025507/ https://www.ncbi.nlm.nih.gov/pubmed/33827689 http://dx.doi.org/10.1186/s12885-021-08028-8 |
Ejemplares similares
-
High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study
por: Zhao, Yanfang, et al.
Publicado: (2021) -
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
por: Chen, Yau-Hung, et al.
Publicado: (2014) -
Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin
por: Hu, Xiaolin, et al.
Publicado: (2021) -
Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019) -
Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients
por: Zheng, Yan-Fu, et al.
Publicado: (2021)